{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:38:28Z","timestamp":1793713108260,"version":"4.6.1"},"reference-count":140,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Thrombotic thrombocytopenic purpura (TTP), an insidious and often devastating thrombotic microangiopathy, represents one of the few true hematologic emergencies. Since the identification of the von Willebrand factor (VWF) cleaving protease ADAMTS13 in the early 21st century, tremendous advances have been made in the diagnosis and treatment of the disease. However, as with many areas of science, new knowledge begets new questions about the pathophysiology of both congenital and immune TTP, which identify gaps in our understanding of the mechanistic effects of ADAMTS13 and its inhibitors. Improvements in the clinical management of patients that have\u2014or are suspected to have\u2014TTP requires further advances in diagnostic testing and identification of clinically relevant biomarkers. In this review, we discuss ADAMTS13-related diagnostic testing in TTP, identify the underlying assumptions that guide the field, and explore avenues of research that promise to improve the lives of patients with the disease.<\/jats:p>","DOI":"10.3389\/fmed.2026.1829389","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:31:00Z","timestamp":1777527060000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The landscape of ADAMTS13-related tests in thrombotic thrombocytopenic purpura: a review"],"prefix":"10.3389","volume":"13","author":[{"given":"Chan","family":"Meng","sequence":"first","affiliation":[{"name":"Division of Hematologic Malignancies and Cellular Therapeutics, Department of Internal Medicine, Institute for Reproductive and Developmental Sciences, University of Kansas Medical Center","place":["Kansas City, KS, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantine","family":"Halkidis","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Cellular Therapeutics, Department of Internal Medicine, Institute for Reproductive and Developmental Sciences, University of Kansas Medical Center","place":["Kansas City, KS, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/0002-9343(52)90022-3","article-title":"An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries; an undescribed disease.","volume":"13","author":"Moschcowitz","year":"1952","journal-title":"Am J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy.","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMra020528","article-title":"Thrombotic microangiopathies.","volume":"347","author":"Moake","year":"2002","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/j.1365-2141.2008.07276.x","article-title":"Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features.","volume":"142","author":"Scully","year":"2008","journal-title":"Br J Haematol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1182\/bloodadvances.2017005124","article-title":"Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015.","volume":"1","author":"Page","year":"2017","journal-title":"Blood Adv."},{"key":"B6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1146\/annurev.pathmechdis.3.121806.154311","article-title":"Pathogenesis of thrombotic microangiopathies.","volume":"3","author":"Zheng","year":"2008","journal-title":"Annu Rev Pathol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1055\/s-2005-925468","article-title":"Pathogenesis of thrombotic thrombocytopenic purpura: adamts13 deficiency and beyond.","volume":"31","author":"Lian","year":"2005","journal-title":"Semin Thromb Hemost."},{"key":"B8","doi-asserted-by":"publisher","first-page":"41059","DOI":"10.1074\/jbc.C100515200","article-title":"Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura.","volume":"276","author":"Zheng","year":"2001","journal-title":"J Biol Chem."},{"key":"B9","doi-asserted-by":"publisher","first-page":"5102","DOI":"10.1182\/blood-2009-07-231597","article-title":"Endothelial cell ADAMTS-13 and VWF: production, release, and VWF string cleavage.","volume":"114","author":"Turner","year":"2009","journal-title":"Blood."},{"key":"B10","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/labinvest.3700275","article-title":"ADAMTS13 is expressed in hepatic stellate cells.","volume":"85","author":"Zhou","year":"2005","journal-title":"Lab Invest."},{"key":"B11","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1160\/TH09-12-0860","article-title":"A splice variant of ADAMTS13 is expressed in human hepatic stellate cells and cancerous tissues.","volume":"104","author":"Shomron","year":"2010","journal-title":"Thromb Haemost."},{"key":"B12","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1182\/blood.V87.10.4235.bloodjournal87104235","article-title":"Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion.","volume":"87","author":"Tsai","year":"1996","journal-title":"Blood."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.","volume":"339","author":"Tsai","year":"1998","journal-title":"N Engl J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1182\/blood.V89.9.3097","article-title":"Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura.","volume":"89","author":"Furlan","year":"1997","journal-title":"Blood."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1016\/S2352-3026(16)30018-7","article-title":"Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy.","volume":"3","author":"Mariotte","year":"2016","journal-title":"Lancet Haematol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1002\/pbc.24612","article-title":"Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features.","volume":"60","author":"Reese","year":"2013","journal-title":"Pediatr Blood Cancer."},{"key":"B17","doi-asserted-by":"publisher","first-page":"4386","DOI":"10.1182\/bloodadvances.2024013421","article-title":"Global prevalence of hereditary thrombotic thrombocytopenic purpura determined by genetic analysis.","volume":"8","author":"Seidizadeh","year":"2024","journal-title":"Blood Adv."},{"key":"B18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/jca.21894","article-title":"Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: a nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura.","volume":"36","author":"Pascual-Izquierdo","year":"2021","journal-title":"J Clin Apher."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.3324\/haematol.2019.216796","article-title":"The international hereditary thrombotic thrombocytopenic purpura registry: key findings at enrollment until 2017.","volume":"104","author":"van Dorland","year":"2019","journal-title":"Haematologica."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1111\/jth.15006","article-title":"ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura.","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost."},{"key":"B21","doi-asserted-by":"publisher","first-page":"638","DOI":"10.3324\/haematol.2022.280768","article-title":"ADAMTS13 conformation is closed in non-immune acquired thrombotic thrombocytopenic purpura of unidentified pathophysiology.","volume":"108","author":"Joly","year":"2023","journal-title":"Haematologica."},{"key":"B22","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1016\/j.htct.2023.11.006","article-title":"Outcomes of thrombotic thrombocytopenic purpura patients submitted to therapeutic plasma exchange in a single center in Brazil.","volume":"46","author":"Terra","year":"2024","journal-title":"Hematol Transfus Cell Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3324\/haematol.2018.198275","article-title":"Clinical factors and biomarkers predict outcome in patients with immune-mediated thrombotic thrombocytopenic purpura.","volume":"104","author":"Staley","year":"2019","journal-title":"Haematologica."},{"key":"B24","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1182\/blood-2016-12-758656","article-title":"Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura.","volume":"130","author":"Alwan","year":"2017","journal-title":"Blood."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1182\/bloodadvances.2022008443","article-title":"Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.","volume":"7","author":"Djulbegovic","year":"2023","journal-title":"Blood Adv."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1111\/jth.15406","article-title":"The standard of care for immune thrombotic thrombocytopenic purpura today.","volume":"19","author":"Zheng","year":"2021","journal-title":"J Thromb Haemost."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1016\/j.jtha.2025.06.002","article-title":"2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura.","volume":"23","author":"Zheng","year":"2025","journal-title":"J Thromb Haemost."},{"key":"B28","doi-asserted-by":"publisher","first-page":"8137","DOI":"10.3390\/ijms25158137","article-title":"ADAMTS13 in the new era of TTP.","volume":"25","author":"Papakonstantinou","year":"2024","journal-title":"Int J Mol Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s00134-025-07981-3","article-title":"Thrombotic thrombocytopenic purpura: early diagnosis and effective treatment in 2025.","volume":"51","author":"Azoulay","year":"2025","journal-title":"Intensive Care Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/asheducation-2018.1.530","article-title":"Clinical and laboratory diagnosis of TTP: an integrated approach.","volume":"2018","author":"Chiasakul","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura.","volume":"115","author":"Kremer Hovinga","year":"2010","journal-title":"Blood."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1182\/blood-2006-02-006064","article-title":"Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity.","volume":"109","author":"Ferrari","year":"2007","journal-title":"Blood."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1055\/s-0038-1668545","article-title":"Relapse rate in survivors of acute autoimmune thrombotic thrombocytopenic purpura treated with or without rituximab.","volume":"118","author":"Falter","year":"2018","journal-title":"Thromb Haemost."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1182\/bloodadvances.2018018432","article-title":"The remarkable diversity of thrombotic thrombocytopenic purpura: a perspective.","volume":"2","author":"George","year":"2018","journal-title":"Blood Adv."},{"key":"B35","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/bjh.13658","article-title":"Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the harvard TMA research collaborative.","volume":"171","author":"Bendapudi","year":"2015","journal-title":"Br J Haematol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1111\/j.1537-2995.2010.02653.x","article-title":"The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange.","volume":"50","author":"Bentley","year":"2010","journal-title":"Transfusion."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3324\/haematol.2011.049676","article-title":"Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA reference center experience.","volume":"97","author":"Benhamou","year":"2012","journal-title":"Haematologica."},{"key":"B38","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/jth.13882","article-title":"External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment.","volume":"16","author":"Li","year":"2018","journal-title":"J Thromb Haemost."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1111\/trf.14230","article-title":"ADAMTS13 test and\/or PLASMIC clinical score in management of acquired thrombotic thrombocytopenic purpura: a cost-effective analysis.","volume":"57","author":"Kim","year":"2017","journal-title":"Transfusion."},{"key":"B40","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1182\/asheducation-2012.1.604","article-title":"Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes.","volume":"2012","author":"George","year":"2012","journal-title":"Hematol Am Soc Hematol Educ Program."},{"key":"B41","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1046\/j.1537-2995.2000.40080896.x","article-title":"Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome.","volume":"40","author":"Rizvi","year":"2000","journal-title":"Transfusion."},{"key":"B42","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1160\/TH17-06-0404","article-title":"Insights into 3D structure of ADAMTS13: a stepping stone towards novel therapeutic treatment of thrombotic thrombocytopenic purpura.","volume":"118","author":"Ercig","year":"2018","journal-title":"Thromb Haemost."},{"key":"B43","doi-asserted-by":"publisher","first-page":"166954","DOI":"10.1016\/j.jmb.2021.166954","article-title":"An integrative structural biology analysis of von willebrand factor binding and processing by ADAMTS-13 in Solution.","volume":"433","author":"Del Amo-Maestro","year":"2021","journal-title":"J Mol Biol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1038\/s41467-019-11474-5","article-title":"Crystal structure and substrate-induced activation of ADAMTS13.","volume":"10","author":"Petri","year":"2019","journal-title":"Nat Commun."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1111\/jth.13688","article-title":"ADAMTS-13 glycans and conformation-dependent activity.","volume":"15","author":"Nowak","year":"2017","journal-title":"J Thromb Haemost."},{"key":"B46","doi-asserted-by":"publisher","first-page":"18584","DOI":"10.1073\/pnas.1413282112","article-title":"Allosteric activation of ADAMTS13 by von Willebrand factor.","volume":"111","author":"Muia","year":"2014","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B47","doi-asserted-by":"publisher","first-page":"102603","DOI":"10.1016\/j.rpth.2024.102603","article-title":"Mechanistic insight into multiple antibody binding to ADAMTS13 in immune thrombotic thrombocytopenic purpura.","volume":"8","author":"Halkidis","year":"2024","journal-title":"Res Pract Thromb Haemost."},{"key":"B48","doi-asserted-by":"publisher","first-page":"5760","DOI":"10.1074\/jbc.M117.776732","article-title":"A model for the conformational activation of the structurally quiescent metalloprotease ADAMTS13 by von Willebrand factor.","volume":"292","author":"South","year":"2017","journal-title":"J Biol Chem."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1182\/blood.2022019252","article-title":"Mechanisms of inhibition of human monoclonal antibodies in immune thrombotic thrombocytopenic purpura.","volume":"141","author":"Halkidis","year":"2023","journal-title":"Blood."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1111\/jth.15332","article-title":"A human monoclonal antibody against the distal carboxyl terminus of ADAMTS-13 modulates its susceptibility to an inhibitor in thrombotic thrombocytopenic purpura.","volume":"19","author":"Halkidis","year":"2021","journal-title":"J Thromb Haemost."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e70189","DOI":"10.1002\/hem3.70189","article-title":"Open or closed? Understanding the molecular mechanisms and clinical implications of ADAMTS13\u2019s conformation.","volume":"9","author":"Bonnez","year":"2025","journal-title":"Hemasphere."},{"key":"B52","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1182\/bloodadvances.2021004971","article-title":"Anti-cysteine\/spacer antibodies that open ADAMTS13 are a common feature in iTTP.","volume":"5","author":"De Waele","year":"2021","journal-title":"Blood Adv."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1182\/bloodadvances.2019001375","article-title":"Antibodies that conformationally activate ADAMTS13 allosterically enhance metalloprotease domain function.","volume":"4","author":"Schelpe","year":"2020","journal-title":"Blood Adv."},{"key":"B54","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3324\/haematol.11739","article-title":"ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.","volume":"93","author":"Peyvandi","year":"2008","journal-title":"Haematologica."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1111\/j.1538-7836.2012.04808.x","article-title":"ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura.","volume":"10","author":"Bettoni","year":"2012","journal-title":"J Thromb Haemost."},{"key":"B56","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/j.1365-2141.2008.07107.x","article-title":"Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse.","volume":"141","author":"Jin","year":"2008","journal-title":"Br J Haematol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1182\/bloodadvances.2019000939","article-title":"Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura.","volume":"3","author":"Sui","year":"2019","journal-title":"Blood Adv."},{"key":"B58","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1160\/TH10-06-0417","article-title":"Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathies.","volume":"105","author":"Palla","year":"2011","journal-title":"Thromb Haemost."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/j.1538-7836.2006.01904.x","article-title":"Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods.","volume":"4","author":"Kremer Hovinga","year":"2006","journal-title":"J Thromb Haemost."},{"key":"B60","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1365-2141.2005.05420.x","article-title":"FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay.","volume":"129","author":"Kokame","year":"2005","journal-title":"Br J Haematol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1016\/j.jtha.2023.08.016","article-title":"Cattle-FRETS71, a novel fluorogenic substrate with broad applicability for characterizing ADAMTS13 properties and function.","volume":"21","author":"Barton","year":"2023","journal-title":"J Thromb Haemost."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1046\/j.1538-7836.2003.00385.x","article-title":"Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods.","volume":"1","author":"Studt","year":"2003","journal-title":"J Thromb Haemost."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1111\/j.1538-7836.2004.00879.x","article-title":"Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas.","volume":"2","author":"Tripodi","year":"2004","journal-title":"J Thromb Haemost."},{"key":"B64","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1160\/TH13-08-0688","article-title":"FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients.","volume":"112","author":"Mancini","year":"2014","journal-title":"Thromb Haemost."},{"key":"B65","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1182\/blood-2003-08-2861","article-title":"VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13.","volume":"103","author":"Kokame","year":"2004","journal-title":"Blood."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1111\/jth.12319","article-title":"An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura.","volume":"11","author":"Muia","year":"2013","journal-title":"J Thromb Haemost."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.thromres.2014.09.006","article-title":"Evaluation of a chromogenic commercial assay using VWF-73 peptide for ADAMTS13 activity measurement.","volume":"134","author":"Joly","year":"2014","journal-title":"Thromb Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/j.1538-7836.2007.02438.x","article-title":"Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies.","volume":"5","author":"Meyer","year":"2007","journal-title":"J Thromb Haemost."},{"key":"B69","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1182\/blood-2004-06-2096","article-title":"Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin.","volume":"105","author":"Studt","year":"2005","journal-title":"Blood."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1182\/blood-2009-01-195461","article-title":"Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site.","volume":"114","author":"Raife","year":"2009","journal-title":"Blood."},{"key":"B71","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1160\/TH12-08-0565","article-title":"Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies.","volume":"109","author":"Mackie","year":"2013","journal-title":"Thromb Haemost."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1111\/j.1537-2995.2006.00914.x","article-title":"Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity.","volume":"46","author":"Kato","year":"2006","journal-title":"Transfusion."},{"key":"B73","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1182\/blood-2009-12-258780","article-title":"The ADAMTS13 metalloprotease domain: roles of subsites in enzyme activity and specificity.","volume":"116","author":"de Groot","year":"2010","journal-title":"Blood."},{"key":"B74","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ab.2006.06.022","article-title":"Creation of a recombinant peptide substrate for fluorescence resonance energy transfer-based protease assays.","volume":"358","author":"Zhang","year":"2006","journal-title":"Anal Biochem."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1046\/j.1365-2141.2001.02622-5.x","article-title":"Low activity of von Willebrand factor-cleaving protease is not restricted to patients suffering from thrombotic thrombocytopenic purpura.","volume":"112","author":"Loof","year":"2001","journal-title":"Br J Haematol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1182\/blood-2002-02-0344","article-title":"Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura.","volume":"100","author":"Bianchi","year":"2002","journal-title":"Blood."},{"key":"B77","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/j.1538-7836.2005.01767.x","article-title":"FRETS-VWF73: a rapid and predictive tool for thrombotic thrombocytopenic purpura.","volume":"4","author":"Groot","year":"2006","journal-title":"J Thromb Haemost."},{"key":"B78","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/trf.13359","article-title":"Effect of ADAMTS13 activity turnaround time on plasma utilization for suspected thrombotic thrombocytopenic purpura.","volume":"56","author":"Connell","year":"2016","journal-title":"Transfusion."},{"key":"B79","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1182\/blood.2025028416","article-title":"Rapid ADAMTS13 activity assays for thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.","volume":"146","author":"Deshpande","year":"2025","journal-title":"Blood."},{"key":"B80","doi-asserted-by":"publisher","first-page":"100108","DOI":"10.1016\/j.rpth.2023.100108","article-title":"ADAMTS13 activity testing: evaluation of commercial platforms for diagnosis and monitoring of thrombotic thrombocytopenic purpura.","volume":"7","author":"Singh","year":"2023","journal-title":"Res Pract Thromb Haemost."},{"key":"B81","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1055\/s-0038-1641151","article-title":"Evaluation of the fully automated HemosIL acustar ADAMTS13 activity assay.","volume":"118","author":"Favresse","year":"2018","journal-title":"Thromb Haemost."},{"key":"B82","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s11239-020-02086-8","article-title":"Evaluation of a rapid turn-over, fully-automated ADAMTS13 activity assay: a method comparison study.","volume":"50","author":"Stratmann","year":"2020","journal-title":"J Thromb Thrombolysis."},{"key":"B83","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/jth.15157","article-title":"A multicenter laboratory assessment of a new automated chemiluminescent assay for ADAMTS13 activity.","volume":"19","author":"Favaloro","year":"2021","journal-title":"J Thromb Haemost."},{"key":"B84","doi-asserted-by":"publisher","first-page":"102525","DOI":"10.1016\/j.rpth.2024.102525","article-title":"A comparative study of anti-ADAMTS-13 antibody dynamics in immune-mediated thrombotic thrombocytopenic purpura.","volume":"8","author":"Cozzi","year":"2024","journal-title":"Res Pract Thromb Haemost."},{"key":"B85","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/ijlh.12542","article-title":"Validation of a panel of ADAMTS13 assays for diagnosis of thrombotic thrombocytopenic purpura: activity, functional inhibitor, and autoantibody test.","volume":"38","author":"Nakashima","year":"2016","journal-title":"Int J Lab Hematol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1055\/s-0039-1696718","article-title":"Evaluation of a new, rapid, fully automated assay for the measurement of ADAMTS13 activity.","volume":"119","author":"Valsecchi","year":"2019","journal-title":"Thromb Haemost."},{"key":"B87","doi-asserted-by":"publisher","first-page":"e193","DOI":"10.1515\/cclm-2020-1020","article-title":"Comparative evaluation of the fully automated HemosIL\u00ae AcuStar ADAMTS13 activity assay vs. ELISA: possible interference by autoantibodies different from anti ADAMTS-13.","volume":"59","author":"Falcinelli","year":"2021","journal-title":"Clin Chem Lab Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMra1813013","article-title":"Hereditary thrombotic thrombocytopenic purpura.","volume":"381","author":"Kremer Hovinga","year":"2019","journal-title":"N Engl J Med."},{"key":"B89","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1182\/blood-2012-01-403113","article-title":"Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura.","volume":"120","author":"Lotta","year":"2012","journal-title":"Blood."},{"key":"B90","doi-asserted-by":"publisher","first-page":"5888","DOI":"10.1182\/blood-2012-02-408914","article-title":"Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura.","volume":"119","author":"Moatti-Cohen","year":"2012","journal-title":"Blood."},{"key":"B91","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1182\/bloodadvances.2023011972","article-title":"Management and follow-up of pregnancy-onset thrombotic thrombocytopenic purpura: the French experience.","volume":"8","author":"B\u00e9ranger","year":"2024","journal-title":"Blood Adv."},{"key":"B92","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1538-7836.2011.04341.x","article-title":"Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan.","volume":"9","author":"Fujimura","year":"2011","journal-title":"J Thromb Haemost."},{"key":"B93","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/ijlh.13557","article-title":"ADAMTS13 testing update: focus on laboratory aspects of difficult thrombotic thrombocytopenic purpura diagnoses and effects of new therapies.","volume":"43","author":"Smock","year":"2021","journal-title":"Int J Lab Hematol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.jtha.2024.02.003","article-title":"Mechanism underlying severe deficiency of plasma ADAMTS-13 activity in immune thrombotic thrombocytopenic purpura.","volume":"22","author":"Zheng","year":"2024","journal-title":"J Thromb Haemost."},{"key":"B95","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/jth.14747","article-title":"Anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura do not hamper ELISA-based quantification of ADAMTS13 antigen.","volume":"18","author":"Dekimpe","year":"2020","journal-title":"J Thromb Haemost."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.3324\/haematol.2011.042945","article-title":"ADAMTS13 activity and antigen during therapy and follow-up of patients with idiopathic thrombotic thrombocytopenic purpura: correlation with clinical outcome.","volume":"96","author":"Yang","year":"2011","journal-title":"Haematologica."},{"key":"B97","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.thromres.2006.07.012","article-title":"Quantitative Western blot analysis of plasma ADAMTS13 antigen in patients with Upshaw-Schulman syndrome.","volume":"120","author":"Ishizashi","year":"2007","journal-title":"Thromb Res."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1111\/j.1538-7836.2006.02025.x","article-title":"Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.","volume":"4","author":"Shelat","year":"2006","journal-title":"J Thromb Haemost."},{"key":"B99","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.ebiom.2015.06.007","article-title":"Pathogenicity of Anti-ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura.","volume":"2","author":"Thomas","year":"2015","journal-title":"EBioMedicine."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1016\/j.jtha.2023.02.011","article-title":"Autoantibodies enhance ADAMTS-13 clearance in patients with immune thrombotic thrombocytopenic purpura.","volume":"21","author":"Underwood","year":"2023","journal-title":"J Thromb Haemost."},{"key":"B101","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1001\/jama.2025.3807","article-title":"Immune thrombotic thrombocytopenic purpura: a review.","volume":"334","author":"Pishko","year":"2025","journal-title":"JAMA."},{"key":"B102","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1160\/TH06-02-0100","article-title":"ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura.","volume":"95","author":"Tsai","year":"2006","journal-title":"Thromb Haemost."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1182\/blood-2004-11-4490","article-title":"ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases.","volume":"106","author":"Rieger","year":"2005","journal-title":"Blood."},{"key":"B104","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1111\/jth.15822","article-title":"ADAMTS13 conformations and mechanism of inhibition in immune thrombotic thrombocytopenic purpura.","volume":"20","author":"Halkidis","year":"2022","journal-title":"J Thromb Haemost."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1111\/trf.13584","article-title":"ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 1. Structural and functional characterization in vitro.","volume":"56","author":"Ostertag","year":"2016","journal-title":"Transfusion."},{"key":"B106","doi-asserted-by":"publisher","first-page":"e329","DOI":"10.1055\/s-0038-1672187","article-title":"Bethesda assay for detecting inhibitory anti-ADAMTS13 antibodies in immune-mediated thrombotic thrombocytopenic purpura.","volume":"2","author":"Vendramin","year":"2018","journal-title":"TH Open."},{"key":"B107","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/978-1-0716-3175-1_33","article-title":"Identification of ADAMTS13 inhibitors in acquired TTP.","volume":"2663","author":"Favaloro","year":"2023","journal-title":"Methods Mol Biol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1146\/annurev-med-061813-013241","article-title":"ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.","volume":"66","author":"Zheng","year":"2015","journal-title":"Annu Rev Med."},{"key":"B109","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1586\/17474086.2016.1122515","article-title":"ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura - current perspectives and new treatment strategies.","volume":"9","author":"Tersteeg","year":"2016","journal-title":"Expert Rev Hematol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/aob-23-46","article-title":"The history of thrombotic thrombocytopenic purpura research: a narrative review.","volume":"9","author":"Halkidis","year":"2024","journal-title":"Ann Blood."},{"key":"B111","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/jth.12494","article-title":"Measurement and prevalence of circulating ADAMTS13-specific immune complexes in autoimmune thrombotic thrombocytopenic purpura.","volume":"12","author":"Lotta","year":"2014","journal-title":"J Thromb Haemost."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.3324\/haematol.2024.285391","article-title":"Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune mechanism.","volume":"110","author":"Simon","year":"2025","journal-title":"Haematologica."},{"key":"B113","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3324\/haematol.2013.094151","article-title":"Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura.","volume":"99","author":"Ferrari","year":"2014","journal-title":"Haematologica."},{"key":"B114","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ejim.2016.11.003","article-title":"ADAMTS13-specific circulating immune complexes as potential predictors of relapse in patients with acquired thrombotic thrombocytopenic purpura.","volume":"39","author":"Mancini","year":"2017","journal-title":"Eur J Intern Med."},{"key":"B115","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1182\/blood.V51.3.559.559","article-title":"Circulating immune complexes in thrombotic thrombocytopenic purpura (TTP).","volume":"51","author":"Neame","year":"1978","journal-title":"Blood."},{"key":"B116","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1046\/j.1537-2995.1980.20180125033.x","article-title":"Plasmapheresis in TTP- clearance of immune complexes.","volume":"20","author":"Sacher","year":"1980","journal-title":"Transfusion."},{"key":"B117","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1538-7836.2011.04548.x","article-title":"Inverse correlation of free and immune complex-sequestered anti-ADAMTS13 antibodies in a patient with acquired thrombotic thrombocytopenic purpura.","volume":"10","author":"Ferrari","year":"2012","journal-title":"J Thromb Haemost."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1111\/j.1538-7836.2009.03568.x","article-title":"IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura.","volume":"7","author":"Ferrari","year":"2009","journal-title":"J Thromb Haemost."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.3324\/haematol.2010.036327","article-title":"Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodies in the spacer domain.","volume":"96","author":"Pos","year":"2011","journal-title":"Haematologica."},{"key":"B120","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1182\/blood-2003-05-1616","article-title":"Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura.","volume":"102","author":"Scheiflinger","year":"2003","journal-title":"Blood."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.jtha.2023.12.028","article-title":"ADAMTS-13 conformation influences autoimmune recognition in immune thrombotic thrombocytopenic purpura.","volume":"22","author":"Underwood","year":"2024","journal-title":"J Thromb Haemost."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.3389\/fimmu.2018.01646","article-title":"Concentration and subclass distribution of anti-ADAMTS13 IgG autoantibodies in different stages of acquired idiopathic thrombotic thrombocytopenic purpura.","volume":"9","author":"Sinkovits","year":"2018","journal-title":"Front Immunol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1182\/bloodadvances.2022008885","article-title":"ADAMTS13 conformation and immunoprofiles in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura.","volume":"7","author":"Sakai","year":"2023","journal-title":"Blood Adv."},{"key":"B124","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1182\/bloodadvances.2020004172","article-title":"Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpura.","volume":"5","author":"Kangro","year":"2021","journal-title":"Blood Adv."},{"key":"B125","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions.","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol."},{"key":"B126","first-page":"57","article-title":"Effector mechanisms activated by human IgG subclass antibodies: clinical and molecular aspects.","volume":"52","author":"Jefferis","year":"1994","journal-title":"Review article. Ann Biol Clin."},{"key":"B127","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/s41577-023-00871-z","article-title":"The unique properties of IgG4 and its roles in health and disease.","volume":"23","author":"Rispens","year":"2023","journal-title":"Nat Rev Immunol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"105672","DOI":"10.1016\/j.jbc.2024.105672","article-title":"What is allosteric regulation? Exploring the exceptions that prove the rule!","volume":"300","author":"McCullagh","year":"2024","journal-title":"J Biol Chem."},{"key":"B129","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1111\/jth.14602","article-title":"Identification of cysteine thiol-based linkages in ADAMTS13 in support of a non-proteolytic regulation of von Willebrand factor.","volume":"17","author":"Rottensteiner","year":"2019","journal-title":"J Thromb Haemost."},{"key":"B130","doi-asserted-by":"publisher","first-page":"eabg4403","DOI":"10.1126\/sciadv.abg4403","article-title":"Crystal structure of ADAMTS13 CUB domains reveals their role in global latency.","volume":"7","author":"Kim","year":"2021","journal-title":"Sci Adv."},{"key":"B131","doi-asserted-by":"publisher","first-page":"18578","DOI":"10.1073\/pnas.1411979112","article-title":"Conformational activation of ADAMTS13.","volume":"111","author":"South","year":"2014","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/j.jtha.2023.03.021","article-title":"Metalloprotease domain latency protects ADAMTS13 against broad-spectrum inhibitors of metalloproteases while maintaining activity toward VWF.","volume":"21","author":"Singh","year":"2023","journal-title":"J Thromb Haemost."},{"key":"B133","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1529\/biophysj.108.131532","article-title":"Mechanistic studies on ADAMTS13 catalysis.","volume":"95","author":"Di Stasio","year":"2008","journal-title":"Biophys J."},{"key":"B134","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13036-018-0102-y","article-title":"AFM imaging reveals multiple conformational states of ADAMTS13.","volume":"13","author":"Yu","year":"2019","journal-title":"J Biol Eng."},{"key":"B135","doi-asserted-by":"publisher","first-page":"100012","DOI":"10.1016\/j.rpth.2022.100012","article-title":"A novel mechanism underlying allosteric regulation of ADAMTS-13 revealed by hydrogen-deuterium exchange plus mass spectrometry.","volume":"7","author":"Pillai","year":"2023","journal-title":"Res Pract Thromb Haemost."},{"key":"B136","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/0003-9861(83)90225-4","article-title":"The determination of thermodynamic allosteric parameters of an enzyme undergoing steady-state turnover.","volume":"224","author":"Reinhart","year":"1983","journal-title":"Arch Biochem Biophys."},{"key":"B137","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/jth.13922","article-title":"An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura.","volume":"16","author":"Roose","year":"2018","journal-title":"J Thromb Haemost."},{"key":"B138","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1182\/blood.2019004221","article-title":"Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura.","volume":"136","author":"Roose","year":"2020","journal-title":"Blood."},{"key":"B139","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1182\/blood.2023023269","article-title":"Peak ADAMTS13 activity to assess ADAMTS13 conformation and risk of relapse in immune-mediated thrombotic thrombocytopenic purpura.","volume":"143","author":"Prasannan","year":"2024","journal-title":"Blood."},{"key":"B140","doi-asserted-by":"publisher","first-page":"6169","DOI":"10.3390\/jcm12196169","article-title":"ADAMTS13 and non-ADAMTS13 biomarkers in immune-mediated thrombotic thrombocytopenic purpura.","volume":"12","author":"Bonnez","year":"2023","journal-title":"J Clin Med."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1829389\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:31:02Z","timestamp":1777527062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1829389\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":140,"alternative-id":["10.3389\/fmed.2026.1829389"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1829389","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"article-number":"1829389"}}